Works matching IS 25233548 AND DT 2025 AND VI 45 AND IP 4

Results: 17

Inhibition of mTOR attenuates the initiation and progression of BRCA1‐associated mammary tumors.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 486, doi. 10.1002/cac2.12663

By:

Baek, Hye Jung;
Han, Geun Hee;
Cho, Eun Joo;
Xu, Jihao;
Ki, Min Kyung;
Park, Eun Jung;
Kim, Tae Hyun;
Shin, Dong Hoon;
Cheong, Heesun;
Deng, Chu‐Xia;
Lim, Sung Chul;
Hwang, Chang‐il;
Hwang, Daehee;
Kim, Sang Soo

Publication type:

Article

Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 476, doi. 10.1002/cac2.12662

By:

Ma, Jianli;
Wang, Jingxuan;
Xu, Ting;
Ouyang, Quchang;
Wang, Xiaojia;
Wang, Jingfen;
Gan, Lu;
Ouyang, Zhong;
Lin, Daren;
Sun, Tao;
Shan, Changping;
Yao, Herui;
Zhang, Baochun;
Li, Zhengguang;
Zhuang, Zhixiang;
Lu, Ying;
Yang, Hongwei;
Huang, Jian;
Yang, Xingwang;
Sun, Hongmei

Publication type:

Article

Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 471, doi. 10.1002/cac2.12661

By:

Malmberg, Ruben;
Agema, Bram C.;
Hofman, Maaike M.;
Oosterveld, Stefani;
Bins, Sander;
Dumoulin, Daphne W.;
Joosse, Arjen;
Aerts, Joachim G. J. V.;
Debets, Reno;
Koch, Birgit C. P.;
van der Veldt, Astrid A. M.;
van Leeuwen, Roelof W. F.;
Mathijssen, Ron H. J.

Publication type:

Article

Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression‐associated transcriptome changes and therapeutic vulnerabilities.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 433, doi. 10.1002/cac2.12660

By:

Pyko, Jonas;
Glaß, Markus;
Rosemann, Julia;
Kappler, Matthias;
Macho, Jana;
Qasem, Sarah;
Hüttelmaier, Stefan;
Eckert, Alexander W.;
Haemmerle, Monika;
Gutschner, Tony

Publication type:

Article

Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 397, doi. 10.1002/cac2.12653

By:

Smolle, Maria Anna;
Wenzl, Florian Alexander;
Szkandera, Joanna;
Scheipl, Susanne;
Liegl‐Atzwanger, Bernadette;
Igrec, Jasminka;
Leithner, Andreas

Publication type:

Article

To what extent is the association between obesity and colorectal cancer risk mediated by systemic inflammation?

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 456, doi. 10.1002/cac2.12659

By:

Safizadeh, Fatemeh;
Mandic, Marko;
Hoffmeister, Michael;
Brenner, Hermann

Publication type:

Article

Single‐cell multi‐omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK‐positive lung cancer.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 422, doi. 10.1002/cac2.12658

By:

Baek, Seungbyn;
Sung, Euijeong;
Kim, Gamin;
Hong, Min Hee;
Lee, Chang Young;
Shim, Hyo Sup;
Park, Seong Yong;
Kim, Hye Ryun;
Lee, Insuk

Publication type:

Article

Efficient 5‐ALA‐photodynamic therapy in nasopharyngeal carcinoma induces an immunoactivation mediated by tumoral extracellular vesicles and associated with immunogenic cell death.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 401, doi. 10.1002/cac2.12656

By:

Trioën, Camille;
Soulier, Thomas;
Massoud, Jacquie;
Bouchez, Clément;
Stoup, Nicolas;
Lefebvre, Anthony;
Dewalle, Anne‐Sophie;
Grolez, Guillaume Paul;
Delhem, Nadira;
Moralès, Olivier

Publication type:

Article

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 442, doi. 10.1002/cac2.12654

By:

Chu, Tianqing;
Zhong, Hua;
Yu, Zhuang;
Wang, Jing;
Zhao, Yanqiu;
Mu, Xiaoqian;
Yu, Xinmin;
Shi, Xun;
Shi, Qingming;
Guan, Maojing;
Ding, Cuimin;
Geng, Nan;
Qian, Jialin;
Han, Baohui

Publication type:

Article

HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 428, doi. 10.1002/cac2.12657

By:

Singer, Christian Fridolin;
Jahn, Stephan Wenzel;
Hlauschek, Dominik;
Heber, Ulrike Maria;
Mang‐Manger, Charlotte;
Egle, Daniel;
Balic, Marija;
Pichler, Angelika;
Pfeiler, Georg;
Kacerovsky‐Strobl, Stephanie;
Suppan, Christoph;
Ritter, Magdalena;
Petru, Edgar;
Greil, Richard;
Bago‐Horvath, Zsuzsanna;
Deutschmann, Christine;
Steger, Günther Georg;
Seifert, Michael;
Fitzal, Florian;
Bartsch, Rupert

Publication type:

Article

Cytotoxic and regulatory T cell interactions calculated from image mass cytometry predict immunochemotherapy response in triple‐negative breast cancer.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 392, doi. 10.1002/cac2.12652

By:

Wang, Xiang;
Dong, Jing;
Li, Jian‐Rong;
Lin, Yupei;
Sahoo, Bikram;
Li, Yong;
Liu, Yanhong;
Ripley, Robert Taylor;
Wu, Jia;
Zhang, Jianjun;
Amos, Christopher I;
Cheng, Chao

Publication type:

Article

Issue Information.

Published in:: Cancer Communications, 2025, v. 45, n. 4, p. 389, doi. 10.1002/cac2.12556
Publication type:: Article

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 411, doi. 10.1002/cac2.12649

By:

Chen, Li;
Wu, Wen‐Ya;
Liang, Fei;
Liu, Guang‐Yu;
Yu, Ke‐Da;
Wu, Jiong;
Di, Gen‐Hong;
Fan, Lei;
Wang, Zhong‐Hua;
Li, Jun‐Jie;
Shao, Zhi‐Ming

Publication type:

Article

Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 406, doi. 10.1002/cac2.12648

By:

Wu, Zheming;
Xiao, Huaping;
Kloeber, Jake A;
Ouyang, Yaobin;
Yin, Ping;
Huang, Jinzhou;
Chen, Bin;
Zhu, Shouhai;
Lu, Jing;
Han, Yiqun;
Tu, Xinyi;
Dragojevic, Sonja;
Luo, Kuntian;
Ting, Adrian T;
Welliver, Meng;
Lou, Zhenkun

Publication type:

Article

Training the synergy between Bacillus Calmette‐Guérin and immune checkpoint‐blocking antibodies in bladder cancer.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 438, doi. 10.1002/cac2.12647

By:

Pichler, Renate;
Thurnher, Martin

Publication type:

Article

Targeting ferroptosis resistance resensitizes metastatic HR<sup>+</sup>HER2<sup>−</sup> breast cancer cells to palbociclib‐hormone therapy.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 460, doi. 10.1002/cac2.12646

By:

Pottier, Charles;
Montero‐Ruiz, Laetitia;
Jehay, Robin;
Wery, Coline;
Baiwir, Dominique;
Mazzucchelli, Gabriel;
Bekisz, Sophie;
Thissen, Romain;
Josse, Claire;
Rorive, Andrée;
Gofflot, Stéphanie;
Dahmani, Ahmed;
Morisset, Ludivine;
Collignon, Joëlle;
Delvenne, Philipe;
Marangoni, Elisabetta;
Noël, Agnès;
Jerusalem, Guy;
Sounni, Nor Eddine

Publication type:

Article

Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity.

Published in:

Cancer Communications, 2025, v. 45, n. 4, p. 465, doi. 10.1002/cac2.12651

By:

Stubenvoll, Antonia;
Schmidt, Maria;
Moeller, Johanna;
Chango, Max Alexander Lingner;
Schultz, Carolyn;
Antoniadou, Olga;
Loeffler‐Wirth, Henry;
Bernhart, Stephan;
Große, Florian;
Thier, Beatrice;
Paschen, Annette;
Anderegg, Ulf;
Simon, Jan C.;
Ziemer, Mirjana;
Schoeder, Clara T.;
Binder, Hans;
Kunz, Manfred

Publication type:

Article